Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives. Quick Links Corporate Presentation Responsibility News Portfolio Responsibility Report Annual Reports Leadership Governance SEC Filings Latest Press Releases October 3, 2022 Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody August 26, 2022 Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement August 24, 2022 Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress All press releases Latest Events Sep 12 2022 Sep 12 2022 Morgan Stanley Global Healthcare Conference Click here for Webcast Aug 2 2022 Aug 2 2022 Q2 2022 Incyte Corporation Earnings Conference Call Click here for Webcast Supporting Materials Q2 2022 Financial and Corporate Update Presentation 3 MB All events
